AASCIT - Journal - All Issues

ISSN: 2375-3900

American Journal of Pharmacy and Pharmacology

The Journal

Manuscript Information

Interactions of Ceftriaxone with Phenylalanine and CT-DNA

American Journal of Pharmacy and Pharmacology
Vol.4 , No. 2, Publication Date: Jun. 13, 2017, Page: 5-9

668 Views Since June 13, 2017, 768 Downloads Since Jun. 13, 2017

Paper in PDF (329K)

Follow on

Authors

[1]	Hakan Sezgin Sayiner, Department of Infectious Diseases, Faculty of Medicine, Adiyaman University, Adiyaman, Turkey.
[2]	Fadhila Othman, Department of Genetic & Bioengineering, Faculty of Engineering & Architecture, Kastamonu University, Kastamonu, Turkey.
[3]	Aisha Abdelsalam, Department of Genetic & Bioengineering, Faculty of Engineering & Architecture, Kastamonu University, Kastamonu, Turkey.
[4]	Cengiz Baloglu, Department of Genetic & Bioengineering, Faculty of Engineering & Architecture, Kastamonu University, Kastamonu, Turkey.
[5]	Yasemin Celik Altunoglu, Department of Genetic & Bioengineering, Faculty of Engineering & Architecture, Kastamonu University, Kastamonu, Turkey.
[6]	Fatma Kandemirli, Kastamonu University, Faculty of Engineering and Architecture, Department of Biomedical Engineering, Kastamonu, Turkey.

Abstract

The interaction of ceftriaxone and phenylalanine with different temperatures and incubation times were determined by Ultraviolet-Visible spectrophotometer (UV) and also interaction between ceftriaxone and Calf-Thymus Deoxyribonucleic acid (CT-DNA) by UV absorbance. Values of binding parameters for ceftriaxone – phenylalanine inreraction in terms of binding constant were found to be 2.4×10⁴, 2.8×10⁴, 1.8×10⁴, 2.0×10⁴, 3.0×10⁵ for 5 minutes incubation time and pH:7. Binding parameter values for Ceftriaxone and CT-DNA at 25°C, 30°C, 40°C and 50°C were found as 3.3×10⁴, 8×10³, 6×10³ and 2.2×10⁴ respectively.

Keywords

Ceftriaxone, Phenylalanine, DNA Interaction

Reference

[01]	Steadman E, Raisch D. W, Bennett, CL, Esterly JS, Becker T, Postelnick, M, Scheetz,. H. (2010). Evaluation of a potential clinical interaction between ceftriaxone and calcium. Antimicrobial agents and chemotherapy, 54(4):1534-40.
[02]	Schaad UB, McCracken GH, Loock CA, Thomas ML. (1981). Pharmacokinetics and bacteriologic efficacy of moxalactam, cefotaxime, cefoperazone, and rocephin in experimental bacterial meningitis. Journal of Infectious Diseases, 143(2):156-63.
[03]	Balant LP, Dayer P, Auckenthaler R. (1985). Clinical pharmacokinetics of the third generation cephalosporins. Clinical pharmacokinetics, 10(2):101-43.
[04]	Valesova H, Mailer J, Havlik J, Hulinska D, Hercogova J. (1995). Long-term results in patients with Lyme arthritis following treatment with ceftriaxone Infection, 24(1): 98-102.
[05]	Li Y, & Lu J. (2006). Chemiluminescence flow‐injection analysis of β‐lactam antibiotics using the luminol–permanganate reaction. Luminescence, 21(4): 251-55.
[06]	Nau R, Sörgel F, Eiffert H. (2010). Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clinical microbiology reviews, 23(4): 58-83.
[07]	Shah VS., Weber RJ, Nahata MC. (2011). Contradictions in contraindications for drug-drug interactions. Annals of Pharmacotherapy, 45(3): 409-11.
[08]	Bradley JS, Wassel, RT, Lee L, Nambiar S. (2009). Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events. Pediatrics, 123(4), e609-e613.
[09]	Valesova H, Mailer J, Havlik J, Hulinska D, Hercogova J. (1995). Long-term results in patients with Lyme arthritis following treatment with ceftriaxone. Infection, 24(1):98-102.
[10]	Kishore K, Raina A, Misra V, Jonas E. (1993). Acute verapamil toxicity in a patient with chronic toxicity: possible interaction with ceftriaxone and clindamycin. Annals of Pharmacotherapy, 27(7-8):877-80.
[11]	Aviv H, & Leder P. (1972). Purification of biologically active globin messenger RNA by chromatography on oligothymidylic acid-cellulose. Proceedings of the National Academy of Sciences, 69(6):1408-12.
[12]	Christianson, DW, Mangani S, Shoham G, Lipscomb, W. N. (1989). Binding of D-phenylalanine and D-tyrosine to carboxypeptidase A. Journal of Biological Chemistry, 264(22), 12849-53.
[13]	Sirajuddin M, Ali S, Badshah. A. (2013). Drug–DNA interactions and their study by UV–Visible, fluorescence spectroscopies and cyclic voltammetry. Journal of Photochemistry and Photobiology B: Biology, 124: 1-19.
[14]	Kong L., Liu Z, Hu X, Liu, S, Li W. (2012). Interaction between insulin and calf thymus DNA, and quantification of insulin and calf thymus DNA by a resonance Rayleigh scattering method. Microchimica Acta, 179(3-4):307-13.
[15]	Kong L., Liu Z, Hu X, Liu S. (2011). Interaction of polymyxin B with ds-DNA, and determination of DNA or polymyxin B via resonance Rayleigh scattering and resonance non-linear scattering spectra. Microchimica Acta, 173(1-2):207-13.
[16]	Pradeep I., Balajothi B, Arunachalam S, Dhivya R, Vinothkanna A, Akbarsha MA., Sekar, S. (2016). Fluorescent active ruthenium (ii) complex units containing bpy or phen or dmp ligands anchored on branched poly (ethylenimine): DNA binding and in vitro biological assessment. RSC Advances, 6(38): 31831-39.
[17]	Sayiner HS, Kandemirli F. (2016) the reaction mechanism study of ceftriaxone. and phenylalanine Journal of International Research in Medical and Pharmaceutical Sciences, 9(2): 83-90.